Efgartigimod for preventing iTTP relapses
Treatments studied
Part of Blood & lymphatic clinical trials.
This study tests a drug called efgartigimod to see if it can prevent relapses in people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) who are currently in remission. It may help by reducing the immune activity that causes the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a history of iTTP (a blood condition where your immune system attacks your own blood cells) and are currently in remission (normal platelet count for at least 90 days).
- Your ADAMTS13 enzyme levels are between 30% and 70% (checked twice, at least a week apart).
- It has been at least 6 months since your last dose of rituximab or similar IV immune-suppressing medication.
- If you take other oral immunosuppressants, your dose has not changed in the last 60 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called efgartigimod, given through a vein, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it safely raises platelet counts and reduces bleeding risk.
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
This study tests whether adding a second medication (Iguratimod) to a lower dose of rituximab helps people with a blood condition called ITP who have not responded well to steroids. The goal is to see if the combination is more effective than rituximab alone at raising and keeping platelet counts stable.
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.
This study collects information from people with immune-mediated thrombotic thrombocytopenic purpura (iTTP) during an acute episode. It aims to better understand and improve care for this rare blood disorder.
Hear when a new Immune-mediated Thrombotic Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.